Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu)
重组抗PD-L1全人源单克隆抗体（江苏怀瑜）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameRecombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Huaiyu Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesJiangsu Huaiyu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A